Cite
A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers.
MLA
Sinn, Angela, et al. “A Randomized, Double Blind, Single Dose, Comparative Study of the Pharmacokinetics, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) and Reference Bevacizumab in Healthy Male Volunteers.” British Journal of Clinical Pharmacology, vol. 88, no. 3, Mar. 2022, pp. 1063–73. EBSCOhost, https://doi.org/10.1111/bcp.15032.
APA
Sinn, A., García-Alvarado, F., Gonzalez, V., Huerga, C., & Bullo, F. (2022). A randomized, double blind, single dose, comparative study of the pharmacokinetics, safety and immunogenicity of MB02 (bevacizumab biosimilar) and reference bevacizumab in healthy male volunteers. British Journal of Clinical Pharmacology, 88(3), 1063–1073. https://doi.org/10.1111/bcp.15032
Chicago
Sinn, Angela, Fernanda García-Alvarado, Veronica Gonzalez, Camino Huerga, and Felicitas Bullo. 2022. “A Randomized, Double Blind, Single Dose, Comparative Study of the Pharmacokinetics, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) and Reference Bevacizumab in Healthy Male Volunteers.” British Journal of Clinical Pharmacology 88 (3): 1063–73. doi:10.1111/bcp.15032.